Unicycive Therapeutics Inc (UNCY)

Jan 7, 2025, 7:00 AM EST - 10 days ago

Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

Nov 21, 2024, 7:00 AM EST - 2 months ago

Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 7:15 AM EST - 2 months ago

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

Nov 11, 2024, 7:00 AM EST - 2 months ago

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Oct 28, 2024, 7:03 AM EDT - 2 months ago

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024

Oct 16, 2024, 4:35 PM EDT - 3 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024

Oct 14, 2024, 7:03 AM EDT - 3 months ago

Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024

Oct 9, 2024, 7:03 AM EDT - 3 months ago

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

Sep 24, 2024, 7:03 AM EDT - 4 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Sep 16, 2024, 7:03 AM EDT - 4 months ago

Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024

Sep 5, 2024, 7:03 AM EDT - 4 months ago

Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 7:03 AM EDT - 4 months ago

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Aug 26, 2024, 7:03 AM EDT - 5 months ago

Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024

Aug 14, 2024, 7:10 AM EDT - 5 months ago

Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 7:03 AM EDT - 6 months ago

Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)

Jul 11, 2024, 7:03 AM EDT - 6 months ago

Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Jul 10, 2024, 7:03 AM EDT - 6 months ago

Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)

Jul 1, 2024, 7:03 AM EDT - 7 months ago

Unicycive Therapeutics Joins Russell Microcap® Index

Jun 25, 2024, 7:30 AM EDT - 7 months ago

Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial

May 28, 2024, 7:03 AM EDT - 8 months ago

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress

May 23, 2024, 7:03 AM EDT - 8 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference

May 15, 2024, 7:03 AM EDT - 8 months ago

Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting

May 13, 2024, 4:16 PM EDT - 8 months ago

Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update

Apr 10, 2024, 7:03 AM EDT - 10 months ago

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Mar 28, 2024, 4:15 PM EDT - 10 months ago

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

Mar 25, 2024, 7:03 AM EDT - 10 months ago

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

Mar 14, 2024, 7:03 AM EDT - 11 months ago

Unicycive Announces $50 Million Private Placement

Mar 13, 2024, 7:03 AM EDT - 11 months ago

Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference

Mar 7, 2024, 4:12 PM EST - 11 months ago

Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)

Mar 4, 2024, 7:03 AM EST - 11 months ago

Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients

Feb 14, 2024, 7:03 AM EST - 1 year ago

Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting

Jan 29, 2024, 7:03 AM EST - 1 year ago

Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference

Jan 23, 2024, 7:03 AM EST - 1 year ago

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

Dec 18, 2023, 7:03 AM EST - 1 year ago

Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis

Nov 29, 2023, 7:03 AM EST - 1 year ago

Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023

Nov 14, 2023, 4:15 PM EST - 1 year ago

Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update

Oct 23, 2023, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)

Sep 6, 2023, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

Aug 29, 2023, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series

Aug 14, 2023, 5:36 PM EDT - 1 year ago

Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update

Jul 21, 2023, 4:30 PM EDT - 1 year ago

CORRECTION FROM SOURCE: 60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

Jul 21, 2023, 9:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

SXTP

Jul 20, 2023, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference

Jul 18, 2023, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology

Jun 29, 2023, 5:04 PM EDT - 1 year ago

Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program

Jun 16, 2023, 7:38 AM EDT - 1 year ago

Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

Jun 9, 2023, 9:00 AM EDT - 1 year ago

Unicycive Therapeutics, Inc. and Alarum Technologies Ltd. Interviews to Air on Bloomberg TV on the RedChip Money Report®

May 16, 2023, 8:29 AM EDT - 1 year ago

Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update

Apr 24, 2023, 7:00 AM EDT - 1 year ago

Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress

Mar 31, 2023, 7:00 AM EDT - 1 year ago

Unicycive Announces Full Year 2022 Financial Results and Provides Business Update